Eskil Söderlind
Vorstandsvorsitzender bei Merozyne Therapeutics AB
Profil
Dr. Eskil Söderlind is an Investment Director for LU Bioscience AB.
He holds a
PhD in molecular biology from Uppsala, an executive MBA diploma and is an associate professor at Lund University.
He has experience from the life science/biotech area.
Dr. Eskil Söderlind has held different management positions which have resulted in several inventions of platform technologies at established companies.
Additional experiences include global business development responsibilities, marketing/licensing operations and strategic analyses of Intellectual Property landscapes.
Aktive Positionen von Eskil Söderlind
Unternehmen | Position | Beginn |
---|---|---|
Merozyne Therapeutics AB
Merozyne Therapeutics AB Pharmaceuticals: MajorHealth Technology Merozyne Therapeutics AB develops and manufactures pharmaceutical products. The company was founded Madeleine Durbeej-Hjalt and Virginie Carmignac and is headquartered in Lund, Sweden. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Eskil Söderlind
Unternehmen | Position | Ende |
---|---|---|
Cytoguide ApS
Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Direktor/Vorstandsmitglied | 20.05.2014 |
Lund University Bioscience AB
Lund University Bioscience AB Investment ManagersFinance Lund University Bioscience AB (LU Bio) is an investment firm located in Lund, Sweden. In May 2007, LU Bio was founded by the parent firm, Lund University Development AB. They specialize in early-stage investments within the life sciences segment. Lund University was founded by the Swedish government in 1666. The university has three main research areas: medicine and pharmaceuticals, globally sustainable societal development, and the life sciences. | Private Equity Investor | 31.12.2012 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Lund University Bioscience AB
Lund University Bioscience AB Investment ManagersFinance Lund University Bioscience AB (LU Bio) is an investment firm located in Lund, Sweden. In May 2007, LU Bio was founded by the parent firm, Lund University Development AB. They specialize in early-stage investments within the life sciences segment. Lund University was founded by the Swedish government in 1666. The university has three main research areas: medicine and pharmaceuticals, globally sustainable societal development, and the life sciences. | Finance |
Cytoguide ApS
Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Health Technology |
Merozyne Therapeutics AB
Merozyne Therapeutics AB Pharmaceuticals: MajorHealth Technology Merozyne Therapeutics AB develops and manufactures pharmaceutical products. The company was founded Madeleine Durbeej-Hjalt and Virginie Carmignac and is headquartered in Lund, Sweden. | Health Technology |